Fix8 approved in Europe
|
|
20 December 2018 |
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
LiquiBandFix8® Open Hernia Mesh Fixation Device approved in Europe
- CE Approval received for cyanoacrylate-based device for open inguinal hernia surgery
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, today announces that it has received CE approval to market and launch its LiquiBandFix8® Open Hernia Mesh Fixation Device in Europe.
The LiquiBandFix8® Open Hernia Mesh Fixation Device is used for atraumatic mesh fixation in open inguinal hernia surgery. The device optimises costs for payors due to the reduced turnaround time of patients without compromising patient care. The device will be marketed and distributed by the Group's direct sales teams in the UK and Germany and through various distributor partners across the EU. This approval augments AMS's existing LiquiBandFix8® laparoscopic fixation device already used in minimally invasive hernia repair.
At present, the laparoscopic device is approved for use in Europe and a number of other markets. AMS has begun the US approval process for the laparoscopic fixation device which is expected to take another two years and to cost approximately £3 million as it will necessitate a full set of clinical trials. These are expected to start early next year, once Investigational Device Exemption with the FDA has been obtained.
Chris Meredith, Chief Executive Officer of Advanced Medical Solutions, said: "LiquiBandFix8® has been receiving positive surgeon feedback and we are very pleased with this latest approval and the early interest the new product has received. The LiquiBandFix8® Open Hernia Mesh Fixation Device follows the existing LiquiBandFix8® laparoscopic device and enables access to the open surgery market. We believe that this innovation from our R&D pipeline will lead to further applications for both devices in the wider market for the use of adhesives internally."
-End -
For further information, please contact:
|
Advanced Medical Solutions Group plc |
Tel: +44 (0) 1606 545508 |
|
Chris Meredith, Chief Executive Officer Mary Tavener, Chief Financial Officer |
|
|
|
|
|
Consilium Strategic Communications |
Tel: +44 (0) 20 3709 5700 |
|
Mary-Jane Elliott / Matthew Neal / Nicholas Brown / Olivia Manser |
AMS@consilium-comms.com |
|
|
|
|
Investec Bank PLC (NOMAD & Broker) |
Tel: +44 (0) 20 7597 5970 |
|
Daniel Adams / Patrick Robb / Gary Clarence |
|
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and wound care markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of products that include tissue adhesives, sutures, haemostats, internal fixation devices, silver alginates, alginates and foams, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and ActivHeal® as well as supplying under white label.
AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in 77 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 650 employees. For more information please see www.admedsol.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Latest directors dealings
- 13 seconds ago Barr (A.G.)
- 7 minutes ago Personal Group Holdings
- 10 minutes ago Grainger
- 38 minutes ago Helios Underwriting
- 59 minutes ago SSE